OBJECTIVE: To evaluate in vitro fertilization (IVF) cycle outcomes in young poor responders treated with a luteal estradiol/gonadotropin-releasing hormone antagonist (E(2)/ANT) protocol versus an oral contraceptive pill microdose leuprolide protocol (OCP-MDL). DESIGN: Retrospective cohort. SETTING: Academic practice. PATIENT(S): Poor responders: 186 women, aged <35 years undergoing IVF with either E(2)/ANT or OCP-MDL protocols. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Clinical pregnancies, oocytes retrieved, cancellation rate. RESULT(S): Patients in the E(2)/ANT group had a greater gonadotropin requirement (71.9 ± 22.2 vs. 57.6 ± 25.7) and lower E(2) level (1,178.6 ± 668 vs. 1,627 ± 889), yet achieved similar numbers of oocytes retrieved and fertilized, and a greater number of embryos transferred (2.3 ± 0.9 vs. 2.0 ± 1.1) with a better mean grade (2.14 ± .06 vs. 2.7 ± 1.8) compared with the OCP/MDL group. The E2/ANT group exhibited a trend toward improved implantation rates (30.5% vs. 21.1%) and ongoing pregnancy rates per started cycle: 44 out of 117 (37%) versus 17 out of 69 (25%). CONCLUSION(S): Poor responders aged <35 years may be treated with the aggressive E(2)/ANT protocol to improve cycle outcomes. Both protocols remain viable options for this group. Adequately powered, randomized clinical comparison appears justified.
OBJECTIVE: To evaluate in vitro fertilization (IVF) cycle outcomes in young poor responders treated with a luteal estradiol/gonadotropin-releasing hormone antagonist (E(2)/ANT) protocol versus an oral contraceptive pill microdose leuprolide protocol (OCP-MDL). DESIGN: Retrospective cohort. SETTING: Academic practice. PATIENT(S): Poor responders: 186 women, aged <35 years undergoing IVF with either E(2)/ANT or OCP-MDL protocols. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Clinical pregnancies, oocytes retrieved, cancellation rate. RESULT(S): Patients in the E(2)/ANT group had a greater gonadotropin requirement (71.9 ± 22.2 vs. 57.6 ± 25.7) and lower E(2) level (1,178.6 ± 668 vs. 1,627 ± 889), yet achieved similar numbers of oocytes retrieved and fertilized, and a greater number of embryos transferred (2.3 ± 0.9 vs. 2.0 ± 1.1) with a better mean grade (2.14 ± .06 vs. 2.7 ± 1.8) compared with the OCP/MDL group. The E2/ANT group exhibited a trend toward improved implantation rates (30.5% vs. 21.1%) and ongoing pregnancy rates per started cycle: 44 out of 117 (37%) versus 17 out of 69 (25%). CONCLUSION(S): Poor responders aged <35 years may be treated with the aggressive E(2)/ANT protocol to improve cycle outcomes. Both protocols remain viable options for this group. Adequately powered, randomized clinical comparison appears justified.
Authors: Prapti Singh; Marli Amin; Erica Keller; Ariel Simerman; Paul Aguilera; Christine Briton-Jones; David L Hill; David H Abbott; Gregorio Chazenbalk; Daniel A Dumesic Journal: J Assist Reprod Genet Date: 2013-03-20 Impact factor: 3.412
Authors: Ariel A Simerman; David L Hill; Tristan R Grogan; David Elashoff; Nigel J Clarke; Ellen H Goldstein; Alexa N Manrriquez; Gregorio D Chazenbalk; Daniel A Dumesic Journal: Fertil Steril Date: 2014-10-24 Impact factor: 7.329
Authors: Kasey A Reynolds; Kenan R Omurtag; Patricia T Jimenez; Julie S Rhee; Method G Tuuli; Emily S Jungheim Journal: Hum Reprod Date: 2013-07-25 Impact factor: 6.918